Evaluating safety and length of unit stay associated with 1-bag chemotherapy desensitization

J Allergy Clin Immunol Pract. 2024 Oct;12(10):2852-2854.e2. doi: 10.1016/j.jaip.2024.06.030. Epub 2024 Jun 25.

Authors

Marielle C Young¹, Chantal Lemoine², Kimberly G Blumenthal³, Aleena Banerji³

Affiliations

¹ Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass. Electronic address: [email protected].
² Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass.
³ Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.

PMID: 38936662
DOI: 10.1016/j.jaip.2024.06.030

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Desensitization, Immunologic* / methods
Drug Hypersensitivity* / diagnosis
Female
Humans
Length of Stay*
Male
Middle Aged

Substances

Antineoplastic Agents